Daniel E. Frigo, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
About Dr. Daniel E. Frigo
Dr. Daniel Frigo received his B.S. in biochemistry from the University of Notre Dame and earned his Ph.D. in molecular and cellular biology from Tulane University. He was then awarded a postdoctoral fellowship and appointed to research scientist within the Department of Pharmacology & Cancer Biology at Duke University Medical Center in Durham, NC. He was appointed to a faculty position as an Assistant Professor at the University of Houston’s Center for Nuclear Receptors & Cell Signaling and the Department of Biology & Biochemistry in 2010. In 2017, he moved his laboratory to The University of Texas MD Anderson Cancer Center where he is currently a tenured Professor in the Departments of Cancer Systems Imaging (primary) and Genitourinary Medical Oncology (secondary). He remains an Adjunct Associate Professor with the University of Houston. Dr. Frigo’s research is focused on understanding the basic biology of prostate cancer for the purpose of developing new therapies to treat the advanced stages of the disease.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Department Chair, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Center for Nuclear Receptors & Cell Signaling, University of Houston, Houston, TX
Professor, Department of Biology and Biochemistry, University of Houston, Houston, TX
Research Interests
The Frigo laboratory is currently focused on understanding how various signaling pathways, such as those regulated by the androgen receptor, CaMKK2, AMPK, mTOR and Myc, drive the progression of prostate cancer. The long-term goal of this work is to exploit these newly uncovered pathways for therapeutic purposes. Interestingly, many of these signaling pathways converge at various metabolic nodes. The end result is a shift in oncogenic metabolism that allows the cancer cells to utilize a diverse array of nutrients to the benefit of the cancer cell.
Education & Training
Degree-Granting Education
| 2003 | Tulane University, New Orleans, LA, USA, PHD, Molecular & Cellular Biology |
| 1998 | University of Notre Dame, Notre Dame, IN, USA, BS, Biochemistry |
Postgraduate Training
| 2003-2009 | Research Fellowship, Pharmacology & Cancer Biology, Duke University Medical Center, Durham, NC |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023
Assistant Affiliate Member, The Houston Methodist Research Institute, Houston, TX, 2012 - 2021
Other Professional Positions
Research Scientist, Duke University Medical Center, Durham, NC, 2009 - 2010
Institutional Committee Activities
Committee Member, GSBS Biochemistry and Cell Biology Program Admissions Committee, 2018 - Present
Committee Member, Conflict of Interest Committee (COIC), 2017 - Present
Professional Memberships
Grant & Contract Support
| Date: | 2023 - 2024 |
| Title: | Revisiting Antiangiogenic Therapy to Target Hormone Sensitive Prostate Cancer Metabolism |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | R01 CA275138 |
| Date: | 2023 - 2026 |
| Title: | Targeting serine and one-carbon metabolism for the treatment of RB-deficient aggressive variant prostate cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| ID: | HT9425-23-1-0424 |
| Date: | 2022 - 2025 |
| Title: | Evaluation of 11C-choline PET as a Biomarker for ATGL-Mediated Lipolysis in Advanced Prostate Cancer |
| Funding Source: | QIAC QPR PROGRAM |
| Role: | Co-Principal Investigator |
| Date: | 2019 - 2024 |
| Title: | Therapeutic Targeting of the Glutamine Transporter SLC1A5 in Advanced Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| ID: | W81XWH-19-1-0410 |
| Date: | 2017 - 2020 |
| Title: | Creation of a novel, flexible T cell therapy to overcome the immunosuppressive tumor microenvironment |
| Funding Source: | William & Ella Owens Medical Research Foundation |
| Role: | Principal Investigator |
| Date: | 2016 - 2020 |
| Title: | Therapeutic Targeting of Autophagy in Prostate Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Principal Investigator |
| ID: | RSG-16-084-01 - TBE |
| Date: | 2016 - 2019 |
| Title: | Engineering Next-Generation Immunotherapies Using Cell Surface-Linked Nanoparticles |
| Funding Source: | Golfers Against Cancer |
| Role: | Principal Investigator |
| Date: | 2015 - 2020 |
| Title: | Genetic & Metabolic Dissection of the CAMKKbeta Signaling Axis in Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | R01 CA184208 |
| Date: | 2014 - 2015 |
| Title: | Metabolic Dissection of Aberrant Glutamine Metabolism in Prostate Cancer |
| Funding Source: | NIH/NIDDK |
| Role: | Subaward PI |
| ID: | U24DK100469 |
| Date: | 2012 - 2015 |
| Title: | Modulation of Branched-Chain Fatty Acids for the Prevention of Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | R03 CA164908 |
| Date: | 2011 - 2013 |
| Title: | Androgenic Regulation of Autophagy in the Prostate |
| Funding Source: | NIH/NIDDK |
| Role: | Principal Investigator |
| ID: | R03 DK092434 |
| Date: | 2009 - 2013 |
| Title: | Nonclassical Signaling of the Androgen Receptor Polyproline Domain |
| Funding Source: | NIH/NIDDK |
| Role: | Principal Investigator |
| ID: | K01 DK084205 |
Selected Publications
Peer-Reviewed Articles
- Koutroumpakis E, Venkatesh N, Aparicio A, Song J, Panaretakis T, Deswal A, Logothetis CJ, Frigo DE, Hahn AW. Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer. Oncologist. e-Pub 2024. PMID: 39557398.
- Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. e-Pub 2024. PMID: 39324992.
- Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. e-Pub 2024. PMID: 39019979.
- Frigo DE. Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment. Cancer Res 84(11):1742-1744, 2024. PMID: 38831750.
- Cao PHA, Dominic A, Lujan FE, Senthilkumar S, Bhattacharya PK, Frigo DE, Subramani E. Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers. Nat Rev Urol. e-Pub 2024. PMID: 38627553.
- Awad D, Cao PHA, Pulliam TL, Spradlin M, Subramani E, Tellman TV, Ribeiro CF, Muzzioli R, Jewell BE, Pakula H, Ackroyd JJ, Murray MM, Han JJ, Leng M, Jain A, Piyarathna B, Liu J, Song X, Zhang J, Klekers AR, Drake JM, Ittmann MM, Coarfa C, Piwnica-Worms D, Farach-Carson MC, Loda M, Eberlin LS, Frigo DE. Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. Cancer Res 84(5):703-724, 2024. e-Pub 2023. PMID: 38038968.
- Hasterok S, Scott TG, Roller DG, Spencer A, Dutta AB, Sathyan KM, Frigo DE, Guertin MJ, Gioeli D. The Androgen Receptor Does Not Directly Regulate the Transcription of DNA Damage Response Genes. Mol Cancer Res 21(12):1329-1341, 2023. PMID: 37698543.
- Xu W, Qadir MMF, Nasteska D, Mota de Sa P, Gorvin CM, Blandino-Rosano M, Evans CR, Ho T, Potapenko E, Veluthakal R, Ashford FB, Bitsi S, Fan J, Bhondeley M, Song K, Sure VN, Sakamuri SSVP, Schiffer L, Beatty W, Wyatt R, Frigo DE, Liu X, Katakam PV, Arlt W, Buck J, Levin LR, Hu T, Kolls J, Burant CF, Tomas A, Merrins MJ, Thurmond DC, Bernal-Mizrachi E, Hodson DJ, Mauvais-Jarvis F. Architecture of androgen receptor pathways amplifying glucagon-like peptide-1 insulinotropic action in male pancreatic β-cells. Cell Rep 42(5):112529, 2023. e-Pub 2023. PMID: 37200193.
- Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CK, Frigo DE. Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology. e-Pub 2023. PMID: 37192413.
- Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Mol Cancer Res 21(1):51-61, 2023. PMID: 36112348.
- Wells C, Liang Y, Pulliam TL, Lin C, Awad D, Eduful B, O'Byrne S, Hossain MA, Catta-Preta CMC, Ramos PZ, Gileadi O, Gileadi C, Couñago RM, Stork B, Langendorf CG, Nay K, Oakhill JS, Mukherjee D, Racioppi L, Means AR, York B, McDonnell DP, Scott JW, Frigo DE, Drewry DH. SGC-CAMKK2-1: A chemical probe for CAMKK2. Cells 12(2), 2023. e-Pub 2023. PMID: 36672221.
- Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, and Frigo DE. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology, 2023. e-Pub 2023. PMID: 37154098.
- Subramani E, Dominic A, Bhattacharya PK, Frigo DE, Bederman I, Vaziri-Gohar A. Editorial: Metabolic regulation under oxidative stress in cancer. Front Oncol 13:1286086, 2023. e-Pub 2023. PMID: 37771445.
- Pulliam TL, Goli P, Awad D, Lin C, Wilkenfeld SR, Frigo DE. Regulation and Role of CAMKK2 in Prostate Cancer. Nature Reviews Urology 16(6):367-380, 2022. PMID: 35474107.
- Sakellakis MJ, Hahn AW, Ramachandran S,Shang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Paaretakis T, Zhang J, Navone NM, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis, 2022. e-Pub 2022.
- Pulliam TL, Awad D, Han JJ, Murray MM, Ackroyd JJ, Goli P, Oakhill JS, Scott JW, Ittmann MM, Frigo DE. Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer. Cells 11(12), 2022. PMID: 35741020.
- Barton M, Frigo DE, Madak-Erdogan Z, Mauvais-Jarvis F, Prossnitz ER. Steroid Hormones and Receptors in Health and Disease: A Research Conference Co-Organized by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH), May 25-27, 2021. FASEB J 35(11):e21858, 2021. PMID: 34634152.
- Eduful BJ, O'Byrne SN, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte JR, Hossain MA, Wells CI, Zuercher WJ, Catta-Preta CMC, Zonzini Ramos P, Santiago AS, Couñago RM, Langendorf CG, Nay K, Oakhill JS, Pulliam TL, Lin C, Awad D, Willson TM, Frigo DE, Scott JW, Drewry DH. Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes. J Med Chem 64(15):10849-10877. e-Pub 2021. PMID: 34264658.
- Lin C, Blessing AM, Pulliam TL, Shi Y, Wilkenfeld SR, Han JJ, Murray MM, Pham AH, Duong K, Brun SN, Shaw RJ, Ittmann MM, Frigo DE. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene 40(9):1690-1705, 2021. e-Pub 2021. PMID: 33531625.
- Subramani E, Frigo DE. Mitochondria in Metabolic Syndrome, Reproduction and Transgenerational Inheritance—Ongoing Debates and Emerging Links. Endocrinology 162(1), 2021. PMID: 33275660.
- Shatnawi A, Abu Rabe DI, Frigo DE. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer. Adv Cancer Res 152:225-262, 2021. e-Pub 2021. PMID: 34353439.
- Frigo DE, Bondesson M, Williams C. Nuclear Receptors: From Molecular Mechanisms to Therapeutics. Essays Biochem 65(6), 2021.
- Chen R, Liang X, Murray MM, Karasik E, Han JJ, Zhu M, Foster BA, Frigo DE, Wang G. A simple quantitative PCR assay to determine TRAMP transgene zygosity. Prostate Cancer Prostatic Dis. e-Pub 2020. PMID: 32895469.
- Dahl HC, Kanchwala M, Thomas-Jardin SE, Sandhu A, Kanumuri P, Nawas AF, Xing C, Lin C, Frigo DE, Delk NA. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence. PLoS One 15(12):e0242970, 2020. e-Pub 2020. PMID: 33326447.
- Dutta P, Salzillo TC, Pudakalakatti S, Gammon ST, Kaipparettu BA, McAllister F, Wagner S, Frigo DE, Logothetis CJ, Zacharias NM, Bhattacharya PK. Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. Cells 8(4), 2019. e-Pub 2019. PMID: 30978984.
- Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol 21(1):86-94, 2019. e-Pub 2018. PMID: 29748904.
- Lin C, Salzillo TC, Bader DA, Wilkenfeld SR, Awad D, Pulliam TL, Dutta P, Pudakalakatti S, Titus M, McGuire SE, Bhattacharya PK, Frigo DE. Prostate Cancer Energetics and Biosynthesis. Adv Exp Med Biol 1210:185-237, 2019. PMID: 31900911.
- White MA, Frigo DE. Regulation of SLC1A4 and SLC1A5 in Prostate Cancer-Response. Mol Cancer Res 16(11):1811-1812, 2018. PMID: 30385664.
- Awad D, Pulliam TL, Lin C, Wilkenfeld SR, Frigo DE. Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches. Curr Opin Pharmacol 41:1-11, 2018. e-Pub 2018. PMID: 29609138.
- Wilkenfeld SR, Lin C, Frigo DE. Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. Steroids 133:2-7, 2018. e-Pub 2017. PMID: 29155216.
- Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, Gallick GE, Titus MA, Nutt LK, Lin SH. Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II. Cancer Res 78(10):2490-2502, 2018. e-Pub 2018. PMID: 29535221.
- White MA, Tsouko E, Lin C, Rajapakshe K, Spencer JM, Wilkenfeld SR, Vakili SS, Pulliam TL, Awad D, Nikolos F, Katreddy RR, Kaipparettu BA, Sreekumar A, Zhang X, Cheung E, Coarfa C, Frigo DE. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr Relat Cancer 25(4):453-469, 2018. e-Pub 2018. PMID: 29431615.
- White MA, Lin C, Rajapakshe K, Dong J, Shi Y, Tsouko E, Mukhopadhyay R, Jasso D, Dawood W, Coarfa C, Frigo DE. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer. Mol Cancer Res 15(8):1017-1028, 2017. e-Pub 2017. PMID: 28507054.
- Khan AS, Frigo DE. A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. Nat Rev Urol 14(3):164-180, 2017. e-Pub 2017. PMID: 28169991.
- Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, La Spada AR, Bast RC, Merchant FA, Coarfa C, Frigo DE. Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy 13(3):506-521, 2017. e-Pub 2016. PMID: 27977328.
- Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun 7:11612, 2016. e-Pub 2016. PMID: 27194471.
- Park JH, Vithayathil S, Kumar S, Sung PL, Dobrolecki LE, Putluri V, Bhat VB, Bhowmik SK, Gupta V, Arora K, Wu D, Tsouko E, Zhang Y, Maity S, Donti TR, Graham BH, Frigo DE, Coarfa C, Yotnda P, Putluri N, Sreekumar A, Lewis MT, Creighton CJ, Wong LC, Kaipparettu BA. Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14(9):2154-2165, 2016. e-Pub 2016. PMID: 26923594.
- Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC Jr, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR Jr, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Frigo DE.. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. PMID: 26799652.
- Blessing AM, Ganesan S, Rajapakshe K, Ying Sung Y, Reddy Bollu L, Shi Y, Cheung E, Coarfa C, Chang JT, McDonnell DP, Frigo DE. Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. Mol Endocrinol 29(10):1426-39, 2015. e-Pub 2015. PMID: 26305679.
- Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6(30):29161-77, 2015. PMID: 26313360.
- Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget 6(31):31997-2012, 2015. PMID: 26378018.
- Tsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis 36(9):1051-60, 2015. e-Pub 2015. PMID: 26088362.
- Popovics P, Frigo DE, Schally AV, Rick FG. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. Expert Opin Ther Targets 19(5):617-32, 2015. e-Pub 2015. PMID: 25600663.
- Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, Zhang A, Xia X, Ilkayeva OR, Xin L, Ittmann MM, Rick FG, Schally AV, Frigo DE. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene 33(45):5251-61, 2014. e-Pub 2013. PMID: 24186207.
- Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, Sharpe MA, Xin L, Frigo DE. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 3:e103, 2014. e-Pub 2014. PMID: 24861463.
- Shi Y, Han JJ, Tennakoon JB, Mehta FF, Merchant FA, Burns AR, Howe MK, McDonnell DP, Frigo DE. Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol 27(2):280-95, 2013. e-Pub 2012. PMID: 23250485.
- Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest 123(1):493-508, 2013. e-Pub 2012. PMID: 23257359.
- Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME. Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol 132(1-2):186-93, 2012. e-Pub 2012. PMID: 22634477.
- Bratton MR, Frigo DE, Segar HC, Nephew KP, McLachlan JA, Wiese TE, Burow ME. The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells. Environ Health Perspect 120(9):1291-6, 2012. e-Pub 2012. PMID: 22609851.
- Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, Burow ME. Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. J Endocrinol 214(1):45-54, 2012. e-Pub 2012. PMID: 22562654.
- Frigo DE, Howe MK, Wittmann BM, Brunner AM, Cushman I, Wang Q, Brown M, Means AR, McDonnell DP. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res 71(2):528-37, 2011. e-Pub 2010. PMID: 21098087.
- Frigo DE, Sherk AB, Wittmann BM, Norris JD, Wang Q, Joseph JD, Toner AP, Brown M, McDonnell DP. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol 23(9):1385-96, 2009. e-Pub 2009. PMID: 19460858.
- Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, McDonnell DP. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23(3):388-401, 2009. e-Pub 2008. PMID: 19106193.
- Frigo DE, Bratton MR, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, Burow ME. Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis 30(1):106-13, 2009. e-Pub 2008. PMID: 18791200.
- Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnell DP. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 68(18):7475-83, 2008. PMID: 18794135.
- Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 7(3):659-69, 2008. PMID: 18347151.
- Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME. AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res 66(17):8373-81, 2006. PMID: 16951146.
- Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol 20(5):971-83, 2006. e-Pub 2006. PMID: 16410316.
- Frigo DE, Vigh KA, Struckhoff AP, Elliott S, Beckman BS, Burow ME, McLachlan JA. Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway. Toxicol Lett 155(2):227-38, 2005. PMID: 15603917.
- Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24(6):1473-80, 2004. PMID: 15138590.
- Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA. Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis 25(2):249-61, 2004. e-Pub 2003. PMID: 14604893.
- Frigo DE, Burow ME, Mitchell KA, Chiang TC, McLachlan JA. DDT and its metabolites alter gene expression in human uterine cell lines through estrogen receptor-independent mechanisms. Environ Health Perspect 110(12):1239-45, 2002. PMID: 12460804.
- Frigo DE, Duong BN, Melnik LI, Schief LS, Collins-Burow BM, Pace DK, McLachlan JA, Burow ME. Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines. J Nutr 132(7):1848-53, 2002. PMID: 12097658.
- Chen F, Li H, Wang Y, Tang X, Lin K, Li Q, Meng C, Shi W, Leo J, Liang X, Zhang J, Van V, Mahmud I, Wei B, Lorenzi PL, Raso MG, Aparicio A, Lu Y, Frigo DE, Gan B, Zhao D. CHD1 Loss Hijacks SREBP2-mediated Cholesterol Biosynthesis to Fuel SPOP-deficient Prostrate Cancer and Confers Resistance to Castration. Nat Cancer.
Patient Reviews
CV information above last modified February 12, 2025